Donate Help Contact The AHA Sign In Home
American Heart Association
Hypertension
Search: search_blue_button Advanced Search
Hypertension. 2007;49:473-480
Published online before print January 8, 2007, doi: 10.1161/01.HYP.0000255946.55091.24
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Data Supplement
Right arrow All Versions of this Article:
49/3/473    most recent
01.HYP.0000255946.55091.24v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by van de Schans, V. A.M.
Right arrow Articles by Blankesteijn, W. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by van de Schans, V. A.M.
Right arrow Articles by Blankesteijn, W. M.
Right arrowPubmed/NCBI databases
*Substance via MeSH
Medline Plus Health Information
*High Blood Pressure
Related Collections
Right arrow Hypertrophy
Right arrow Animal models of human disease
Right arrow Cell signalling/signal transduction
Right arrow Genetically altered mice
Right arrow Hypertension - basic studies
Right arrowRelated Article

(Hypertension. 2007;49:473.)
© 2007 American Heart Association, Inc.


Original Articles

Interruption of Wnt Signaling Attenuates the Onset of Pressure Overload-Induced Cardiac Hypertrophy

Veerle A.M. van de Schans; Susanne W.M. van den Borne; Agnieszka E. Strzelecka; Ben J.A. Janssen; Jos L.J. van der Velden; Ramon C.J. Langen; Antony Wynshaw-Boris; Jos F.M. Smits; W. Matthijs Blankesteijn

From the Department of Pharmacology and Toxicology (V.A.M.v.d.S., S.W.M.v.d.B., A.E.S., B.J.A.J., J.F.M.S., W.M.B.), Cardiovascular Research Institute Maastricht, Department of Respiratory Medicine (J.L.J.v.d.V., R.C.J.L.), Maastricht University, Maastricht, the Netherlands; and Howard Hughes Medical Institute (A.W.-B.), University of California, San Diego.

Correspondence to W. Matthijs Blankesteijn, Department of Pharmacology and Toxicology, CARIM, Maastricht University, PO Box 616, 6200 MD Maastricht, the Netherlands. E-mail Wm.Blankesteijn{at}FARMACO.unimaas.nl

The hypertrophic response of the heart has been recognized recently as the net result of activation of prohypertrophic and antihypertrophic pathways. Here we report the involvement of the Wnt/Frizzled pathway in the onset of cardiac hypertrophy development. Stimulation of the Wnt/Frizzled pathway activates the disheveled (Dvl) protein. Disheveled subsequently can inhibit glycogen synthase kinase-3ß, a protein with potent antihypertrophic actions through diverse molecular mechanisms. In the Wnt/Frizzled pathway, inhibition of glycogen synthase kinase-3ß leads to an increased amount of ß-catenin, which can act as a transcription factor for several hypertrophy-associated target genes. In this study we subjected mice lacking the Dvl-1 gene and their wild-type littermates to thoracic aortic constriction for 7, 14, and 35 days. In mice lacking the Dvl-1 gene, 7 days of pressure overload-induced increases in left ventricular posterior wall thickness and expression of atrial natriuretic factor and brain natriuretic protein were attenuated compared with their wild-type littermates. ß-Catenin protein amount was reduced in the group lacking the Dvl-1 gene, and an increased glycogen synthase kinase-3ß activity was observed. Moreover, the increase in the amount of Ser473-phosphorylated Akt, a stimulator of cardiac hypertrophy, was lower in the group lacking the Dvl-1 gene. In conclusion, we have demonstrated that interruption of Wnt signaling in the mice lacking the Dvl-1 gene attenuates the onset of pressure overload-induced cardiac hypertrophy through mechanisms involving glycogen synthase kinase-3ß and Akt. Therefore, the Wnt/Frizzled pathway may provide novel therapeutic targets for antihypertrophic therapy.


Key Words: hypertrophy • Wnt • cell signaling • glycogen synthase kinase-3ß • Akt


Related Article:

Cardiac Hypertrophy and the Wnt/Frizzled Pathway
Oscar H. Cingolani
Hypertension 2007 49: 427-428. [Full Text] [PDF]



This article has been cited by other articles:


Home page
DevelopmentHome page
E. D. Cohen, Y. Tian, and E. E. Morrisey
Wnt signaling: an essential regulator of cardiovascular differentiation, morphogenesis and progenitor self-renewal
Development, March 1, 2008; 135(5): 789 - 798.
[Abstract] [Full Text] [PDF]


Home page
Sci SignalHome page
T. Force, K. Woulfe, W. J. Koch, and R. Kerkela
Molecular Scaffolds Regulate Bidirectional Crosstalk Between Wnt and Classical Seven-Transmembrane Domain Receptor Signaling Pathways
Sci. Signal., July 31, 2007; 2007(397): pe41 - pe41.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
O. H. Cingolani
Cardiac Hypertrophy and the Wnt/Frizzled Pathway
Hypertension, March 1, 2007; 49(3): 427 - 428.
[Full Text] [PDF]